Paragon Capital Management LLC raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 28.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 299,538 shares of the company’s stock after purchasing an additional 65,696 shares during the period. Teva Pharmaceutical Industries Limited comprises about 3.2% of Paragon Capital Management LLC’s portfolio, making the stock its 17th largest holding. Paragon Capital Management LLC’s holdings in Teva Pharmaceutical Industries Limited were worth $9,950,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Bronfman E.L. Rothschild L.P. increased its stake in Teva Pharmaceutical Industries Limited by 7.8% during the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after purchasing an additional 261 shares during the last quarter. Kistler Tiffany Companies LLC increased its stake in Teva Pharmaceutical Industries Limited by 74.7% during the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after purchasing an additional 1,571 shares during the last quarter. FNY Managed Accounts LLC bought a new stake in Teva Pharmaceutical Industries Limited during the first quarter valued at $123,000. Sterling Investment Advisors Ltd. increased its stake in Teva Pharmaceutical Industries Limited by 2.6% during the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after purchasing an additional 100 shares during the last quarter. Finally, Cutler Capital Management LLC bought a new stake in Teva Pharmaceutical Industries Limited during the second quarter valued at $133,000. Hedge funds and other institutional investors own 56.76% of the company’s stock.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by ($0.07). The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. Teva Pharmaceutical Industries Limited’s revenue was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.25 EPS.

The company also recently declared a quarterly dividend, which was paid on Thursday, September 14th. Investors of record on Tuesday, August 29th were issued a $0.085 dividend. This represents a $0.34 annualized dividend and a yield of 1.98%. The ex-dividend date was Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is -15.36%.

WARNING: This report was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/09/25/paragon-capital-management-llc-acquires-65696-shares-of-teva-pharmaceutical-industries-limited-teva.html.

Several analysts have weighed in on the stock. Vetr lowered shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $32.27 target price for the company. in a research note on Tuesday, July 4th. BidaskClub upgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research note on Wednesday, July 5th. Wells Fargo & Company reiterated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Tuesday, June 27th. Jefferies Group LLC reiterated a “hold” rating and set a $33.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Friday, June 23rd. Finally, Cantor Fitzgerald set a $31.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research note on Thursday, June 22nd. Five research analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited presently has a consensus rating of “Hold” and a consensus price target of $30.91.

Teva Pharmaceutical Industries Limited Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.